Evidence map›Paper›PMID 40955425›Full record

ArticleMolecular therapy. Oncology2025

Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells

Sandra Tuyaerts, Xenia Geeraerts, Alberto Reale, Latoya Stevens, Giada Bertazzon, Jack Brons, Toon Janssen, Ivan Van Riet, Arianna Calistri, Bart Neyns

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sandra TuyaertsLaboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Xenia GeeraertsLaboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Alberto RealeDepartment of Molecular Medicine, University of Padua, 35121 Padua, Italy.
Latoya StevensLaboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Giada BertazzonLaboratory for Molecular and Cellular Therapies (LMCT), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Jack BronsDepartment of Genetics, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Toon JanssenDepartment of Genetics, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Ivan Van RietDepartment of Hematology and Stem Cell Laboratory, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Arianna CalistriDepartment of Molecular Medicine, University of Padua, 35121 Padua, Italy.
Bart NeynsLaboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses (OVs) are promising anti-cancer agents designed to induce cancer cell death while simultaneously stimulating immune responses through encoded transgenes. FMS-like tyrosine kinase 3 ligand (FLT3L), a critical cytokine in dendritic cell (DC) biology, was incorporated into a genetically engineered OV derived from herpes simplex virus type 1. This virus was modified with deletions in the

Indexed as

conventional dendritic cellsFLT3Lglioblastomaherpes simplex virus type 1immunogenic cell deathmelanomaMT: Regular Issueoncolytic viruspancreatic carcinoma

Identifiers

PMID40955425
PMCPMC12433480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.